Akagera liposomal long-acting injectable antibiotic

Akagera liposomal long-acting injectable antibiotic is a preclinical therapeutic candidate being developed by Akagera Medicines for the treatment of tuberculosis (TB). The formulation utilizes a small molecule antibiotic encapsulated within liposomal nanoparticles, designed as a long-acting injectable (LAI) to provide sustained therapeutic levels over an extended period. Its primary mechanism of action involves phagocytosis-mediated uptake by macrophages, which are the primary cellular reservoir for *Mycobacterium tuberculosis*. By targeting these cells directly, the drug aims to enhance efficacy at the site of infection while potentially reducing systemic side effects and improving patient compliance through less frequent dosing compared to standard daily oral regimens.

Other names

Akagera TB LAIliposomal long-acting injectable antibiotic (tuberculosis)Akagera Medicines TB LAI